PepGen slumps as FDA places hold on lead drug Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

#Shares in #PepGen were down more than 21% after the #FDA placed a #partialclinicalhold on its lead drug PGN-EDODM1, for rare genetic muscle disorder #myotonicdystrophytype1 (DM1).